Jatenzo and Diphenhydramine Interaction: What You Need to Know

What Is Jatenzo and How Does It Work?

Jatenzo is the first FDA-approved oral testosterone replacement therapy formulated as a self-emulsifying drug delivery system (SEDDS), approved in March 2019 for adult men with classical hypogonadism. Each softgel capsule contains testosterone undecanoate (TU), a lipophilic ester of testosterone that is absorbed via intestinal lymphatics, bypassing first-pass hepatic metabolism almost entirely.

Absorption Pathway

Because Jatenzo depends on dietary fat to drive lymphatic uptake, patients take it twice daily with food. The FDA label specifies a minimum fat content of approximately 15 grams per meal to achieve adequate absorption. Peak serum testosterone (Cmax) occurs at roughly 4 hours post-dose. In the key open-label trial by Khera et al. Supporting approval (N=166, 16 weeks), 87% of men achieved average testosterone concentrations within the normal range of 300 to 1,000 ng/dL. [1]

Metabolism and Elimination

After lymphatic absorption, TU is cleaved by plasma esterases to testosterone and undecanoic acid. Testosterone itself is metabolized primarily in the liver via CYP3A4 to androstenedione, estradiol, and dihydrotestosterone (DHT). P-glycoprotein (P-gp) plays a minor role in intestinal efflux. The FDA Jatenzo prescribing information lists strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) and inducers (e.g., rifampin) as agents that may meaningfully alter TU exposure, but does not flag diphenhydramine specifically. [2]

What Is Diphenhydramine and What Does It Do?

Diphenhydramine is a first-generation H1 antihistamine available over the counter under brand names including Benadryl, ZzzQuil, and Unisom SleepTabs. At standard OTC doses of 25 to 50 mg, it blocks peripheral and central histamine H1 receptors, producing antihistamine, sedative, and antiemetic effects.

Anticholinergic Burden

Beyond histamine blockade, diphenhydramine is a potent muscarinic receptor antagonist. The Anticholinergic Cognitive Burden (ACB) Scale assigns diphenhydramine a score of 3 (the highest tier), indicating strong anticholinergic potential. [3] Muscarinic blockade in the bladder detrusor muscle reduces contractile force and can precipitate urinary retention, a concern of particular weight in men already at risk because of hypogonadism-associated lower urinary tract symptoms.

CYP Profile of Diphenhydramine

Diphenhydramine is metabolized primarily by CYP2D6, with minor contributions from CYP1A2 and CYP3A4. [4] Because Jatenzo's absorption is driven by lymphatic transport and its testosterone metabolite uses CYP3A4, a minor shared pathway exists. However, diphenhydramine is a weak-to-moderate CYP2D6 inhibitor, not a CYP3A4 inhibitor of clinical significance at typical doses. A formal pharmacokinetic interaction study between oral testosterone undecanoate and diphenhydramine has not been published in the peer-reviewed literature as of early 2025.

Pharmacokinetic Interaction: Low Severity

At standard doses of 25 to 50 mg, diphenhydramine does not meaningfully inhibit CYP3A4 or P-gp. Testosterone undecanoate's bioavailability is therefore not expected to change. No dose adjustment of Jatenzo is indicated solely because of diphenhydramine co-administration.

CYP3A4 Overlap: Why It Matters Less Than It Sounds

Drugs that share a metabolic enzyme can interact if one saturates the enzyme or inhibits its activity. Diphenhydramine's CYP3A4 contribution at 50 mg is negligible compared to potent inhibitors like ritonavir (which can raise testosterone AUC by more than 2-fold). [2] For clinical reference, the FDA defines a strong CYP3A4 inhibitor as one producing a 5-fold or greater increase in the AUC of a sensitive substrate. Diphenhydramine does not meet that threshold.

P-gp Considerations

Some antihistamines weakly interact with P-gp transport, but diphenhydramine does not appear on the FDA's list of clinically relevant P-gp inhibitors. [5] Intestinal efflux of TU by P-gp is a theoretical concern during SEDDS formulation development, but no clinical PK data link diphenhydramine to altered TU bioavailability.

Pharmacodynamic Interaction: Moderate Severity

This is where the real clinical story sits. Both Jatenzo and diphenhydramine affect the CNS and the autonomic nervous system, and those effects can add together in ways that matter for men taking testosterone replacement therapy.

Additive CNS Sedation

Testosterone itself is not a conventional CNS depressant, but the Jatenzo FDA label includes warnings regarding CNS effects secondary to polycythemia-related changes and cardiovascular events. Diphenhydramine, by contrast, directly depresses the CNS. At 50 mg, it produces measurable impairment in reaction time and sustained attention. A 2019 study published in the Journal of Clinical Psychopharmacology (N=22 healthy adults) demonstrated that diphenhydramine 50 mg significantly impaired simulated driving performance compared to placebo (P<0.01). [6]

Men on Jatenzo who are also fatigued from suboptimal testosterone levels during dose titration should be cautioned that adding 50 mg diphenhydramine at bedtime compounds any baseline fatigue or cognitive fog.

Urinary Retention and Prostatic Symptoms

Jatenzo's prescribing information carries a warning about potential worsening of benign prostatic hyperplasia (BPH), with monitoring of prostate-specific antigen (PSA) recommended at 3 to 6 months after initiation and then per standard guidelines. [2] Diphenhydramine's muscarinic blockade independently raises the risk of urinary retention and hesitancy. In men with pre-existing BPH, the combination can convert borderline lower urinary tract symptoms into frank retention requiring catheterization.

The 2023 American Urological Association (AUA) BPH Guideline specifically lists antihistamines with high anticholinergic potency as agents to avoid or use with caution in men with BPH. [7]

Cardiovascular Overlap

Jatenzo carries a boxed warning for increases in blood pressure that can raise the risk of major adverse cardiac events. In the JATENZO key study, mean systolic blood pressure increased by approximately 3.9 mmHg from baseline at 16 weeks. [2] Diphenhydramine at high doses can cause tachycardia through its anticholinergic mechanism, transiently elevating heart rate. For most otherwise healthy men, this is not clinically significant. In men with pre-existing hypertension or cardiovascular disease already taking antihypertensives, adding regular diphenhydramine use may complicate blood pressure management.

Who Is Most at Risk?

Not every man on Jatenzo faces equal risk from diphenhydramine. Risk stratification helps identify who needs the most careful counseling.

Higher-Risk Patient Profile

Men over 60 years of age experience greater sensitivity to anticholinergic drugs because of age-related reductions in central cholinergic reserve. The 2019 American Geriatrics Society (AGS) Beers Criteria explicitly list diphenhydramine as a medication to avoid in older adults, citing risks of confusion, urinary retention, and falls. [8] Testosterone replacement in older men is already a carefully managed clinical decision; layering a high-ACB-score drug on top demands physician review.

Men with BPH, a prior history of urinary retention, or a PSA above 4 ng/mL should avoid chronic diphenhydramine use while on Jatenzo. A single nighttime dose taken once for acute allergy symptoms carries lower risk than nightly use for 2 weeks as a sleep aid.

Lower-Risk Patient Profile

Young men (ages 18 to 40) with classical hypogonadism (e.g., Klinefelter syndrome or pituitary disease), no cardiovascular comorbidities, no urinary symptoms, and normal baseline hematocrit who take diphenhydramine 25 mg occasionally for seasonal allergies face minimal additional risk. Occasional use at the lowest effective dose (25 mg rather than 50 mg) limits anticholinergic exposure.

Monitoring Parameters When Co-Use Occurs

The Jatenzo REMS program and FDA label already define mandatory monitoring requirements. Diphenhydramine co-use does not add new laboratory tests, but it does heighten the clinical relevance of existing monitoring targets.

What to Monitor

Blood pressure should be checked at each follow-up visit, particularly if the patient reports regular diphenhydramine use. Hematocrit must be measured at 3 to 6 months after starting Jatenzo (a hematocrit above 54% warrants dose reduction or interruption). [2] PSA and a symptom-based assessment of lower urinary tract function (using the International Prostate Symptom Score, IPSS) are appropriate at 3 to 6 months in any man with BPH risk factors.

No routine ECG monitoring is indicated solely from this drug combination, but men reporting new palpitations while using both agents should be evaluated.

Patient-Reported Symptoms to Watch

Patients should be told to report unusual sleepiness during the day, difficulty starting urination, a sensation of incomplete bladder emptying, or increased thirst (diphenhydramine reduces salivation, which can be mistaken for diabetes insipidus in men on testosterone). Any new or worsening erectile dysfunction is worth reporting, as both hypogonadism treatment titration and anticholinergic load may affect sexual function.

Dose and Timing Considerations

The following framework can guide clinicians and patients through decisions about short-term versus long-term diphenhydramine use while on Jatenzo.

Single-dose, acute use (e.g., one 25 mg tablet for an allergic reaction): Acceptable in most patients. Counsel the patient not to drive for 6 to 8 hours after the dose, as diphenhydramine's sedative half-life averages approximately 9 hours. No Jatenzo dose adjustment needed.

Short-course use (3 to 5 days for acute upper respiratory allergy): Acceptable with caution in men without BPH. Recommend 25 mg rather than 50 mg to reduce anticholinergic burden. Monitor for urinary symptoms daily.

Chronic nightly use (for insomnia, more than 2 consecutive weeks): Discouraged. Diphenhydramine tolerance for the sedative effect develops within 3 to 4 days, making it ineffective as a chronic sleep aid. [9] The persisting anticholinergic effect without sedative benefit represents a net harm in men on Jatenzo. A prescribing clinician should evaluate the insomnia separately and consider evidence-based alternatives such as cognitive behavioral therapy for insomnia (CBT-I), low-dose doxepin 3 to 6 mg (FDA-approved for sleep maintenance insomnia), or melatonin receptor agonists.

Second-generation antihistamines (cetirizine, loratadine, fexofenadine) have substantially lower ACB scores (0 to 1) and do not produce clinically meaningful CNS sedation at standard doses. These represent preferred alternatives for men on Jatenzo who need ongoing allergy management.

What Jatenzo's FDA Label Actually Says About Drug Interactions

The full Jatenzo prescribing information (NDA 208089) identifies the following drug interaction categories explicitly. [2]

Insulin and oral hypoglycemics: Androgens may decrease blood glucose, requiring dose adjustment. Anticoagulants: Testosterone may increase anticoagulant activity of warfarin; INR should be monitored. Corticosteroids: Concurrent use may increase fluid retention. Strong CYP3A4 inhibitors and inducers: Affect testosterone exposure as noted above.

Diphenhydramine does not appear in the Jatenzo interaction table. The absence of a labeled interaction does not mean absence of pharmacodynamic overlap. The FDA label cannot list every pharmacodynamic combination; that responsibility falls to the prescribing clinician.

What the Evidence Says About Anticholinergics and Testosterone

The relationship between anticholinergic burden and androgen physiology is underexplored. A cross-sectional analysis published in Andrology (2022, N=847 community-dwelling men aged 40 to 79) found that men with higher cumulative anticholinergic scores had lower free testosterone concentrations after adjusting for age and BMI, though the mechanism was not established and causality cannot be inferred from cross-sectional data. [10] This finding does not change management recommendations today, but it suggests that reducing unnecessary anticholinergic exposure aligns with broader goals of testosterone optimization.

As the Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend against the use of testosterone therapy in men who are actively trying to father a child, and in men with untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, or a hematocrit greater than 50%." [11] Anticholinergic agents that worsen lower urinary tract symptoms therefore conflict with the conditions under which Jatenzo is safest to use.

Counseling Points for Patients

Men taking Jatenzo should be told the following before reaching for an OTC diphenhydramine product.

Tell your prescriber you are taking Jatenzo before using any OTC sleep aid, cold medicine, or allergy tablet, because many products contain diphenhydramine even when that is not the primary marketed purpose (for example, Nyquil, Tylenol PM, and Advil PM all contain diphenhydramine).

If you need an antihistamine for allergies, ask about cetirizine (Zyrtec) or loratadine (Claritin) first. These are equally effective for allergic rhinitis and carry far less CNS and bladder risk.

Do not drive or operate heavy machinery for at least 8 hours after taking diphenhydramine. This applies regardless of whether you are on Jatenzo.

If you notice difficulty urinating after taking diphenhydramine while on Jatenzo, stop the diphenhydramine and contact your prescriber. Do not wait to see if it resolves on its own if you have not urinated in more than 6 hours.

Report your blood pressure reading at your next visit. Home blood pressure monitoring, twice daily for 7 days after starting any new medication including OTC products, gives your prescriber useful data.